Open Access

Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma

  • Authors:
    • Takahiro Einama
    • Shigeto Ueda
    • Hitoshi Tsuda
    • Kazuhiro Ogasawara
    • Kazuo Hatsuse
    • Osamu Matsubara
    • Satoru Todo
    • Junji Yamamoto
  • View Affiliations

  • Published online on: March 15, 2012     https://doi.org/10.3892/etm.2012.518
  • Pages: 931-936
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Recent studies indicate the clinical significance of the cellular localization of epidermal growth factor receptor (EGFR) in a variety of cancer types. Internalization of activated EGFR is reported to be closely associated with patient prognosis. This study investigated the clinical significance of the immunohistochemical localization of EGFR in patients with metastatic pancreatic cancers compared to those with surgically resected pancreatic cancers. Using 44 surgically resected primary pancreatic cancers and 40 primary or metastatic tumors from 20 autopsied patients with far advanced pancreatic cancers, the incidence of membranous and cytoplasmic EGFR overexpression was compared between primary tumors and far advanced tumors by immunohistochemistry using the Dako EGFR pharmDx™ kit, a global standard kit for EGFR assay. In the 44 surgically resected cancers, 13 (30%) exhibited membranous overexpression of EGFR, comprising 1 case (2%) with score 3+ and 12 cases (27%) with score 2+ and 10 (23%) exhibited cytoplasmic overexpression of EGFR. In the 40 tumors at a far advanced stage, the percentage of samples exhibiting positivity for membranous and cytoplasmic EGFR overexpression was 48% (19 of 40) comprising 7 (18%) with score 2+ and 12 (30%) with score 3+ and 33% (13 of 40), respectively. The far advanced tumors tended to show membranous and cytoplasmic EGFR overexpression more frequently than the surgically resected tumors, although the difference was not significant. These findings suggest that membranous and cytoplasmic overexpression of EGFR may be indicative of the potential aggressiveness of pancreatic cancers.
View Figures
View References

Related Articles

Journal Cover

June 2012
Volume 3 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Einama T, Ueda S, Tsuda H, Ogasawara K, Hatsuse K, Matsubara O, Todo S and Yamamoto J: Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Exp Ther Med 3: 931-936, 2012
APA
Einama, T., Ueda, S., Tsuda, H., Ogasawara, K., Hatsuse, K., Matsubara, O. ... Yamamoto, J. (2012). Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Experimental and Therapeutic Medicine, 3, 931-936. https://doi.org/10.3892/etm.2012.518
MLA
Einama, T., Ueda, S., Tsuda, H., Ogasawara, K., Hatsuse, K., Matsubara, O., Todo, S., Yamamoto, J."Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma". Experimental and Therapeutic Medicine 3.6 (2012): 931-936.
Chicago
Einama, T., Ueda, S., Tsuda, H., Ogasawara, K., Hatsuse, K., Matsubara, O., Todo, S., Yamamoto, J."Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma". Experimental and Therapeutic Medicine 3, no. 6 (2012): 931-936. https://doi.org/10.3892/etm.2012.518